Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?

ABSTRACT:

Background

The Oncotype DX recurrence score (RS) is used as a tool for making decisions about chemotherapy for patients who have hormone receptor (estrogen receptor or progesterone receptor)-positive, HER2-negative breast cancer. There is no benefit from chemotherapy among patients aged ≥50 years who have lymph node-negative disease and an RS from 11 to 25, but the benefit of chemotherapy in the lymph node-positive group remains unknown.

Methods

On the basis of data from the National Cancer Data Base between 2010 and 2014, a nationwide, retrospective cohort study included 73,185 women who had stage I through IIIA breast cancer and an RS between 11 and 30.

Results

Receipt of chemotherapy was associated with a reduced risk of death among patients who had lymph node-posi

SUBMITTER: Ibraheem AF 

PROVIDER: S-EPMC6329644 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature